Fenretinide in Healthy Young Women at Genetic and Familial Risk - Full Text View - ClinicalTrials.gov

  Eligibility

Ages Eligible for Study:	20 Years to 46 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. 20-46 years old women with a known BRCA ½ mutation or with a risk of being a mutation carrier ≥20%.
2. Performance status =0
3. Willingness to avoid pregnancy during treatment and 12 months after drug cessation
4. No clinical and radiological evidence of breast cancer and ovarian disease
5. Signed informed consent

Exclusion Criteria:

1. History of breast cancer or any other malignancy with the exclusion of CIN and non-melanoma skin cancer
2. Child bearing or breast feeding
3. Genetic test result (BRCA)=true negative
4. Blood test alterations (grade ≥2 based on the NCI Common Toxicity Criteria)
5. Previous or concurrent use of SERMs, e.g. tamoxifen (for more than 12 months; if less, a two-months wash-out is required before entering the study)
6. Severe psychiatric disorders or inability to comply to the protocol procedures
7. Any other factor that, at the investigator's discretion, contraindicates the use of fenretinide

http://clinicaltrials.gov/ct2/show/NCT01479192?term=ovarian+cancer&recr=Open&lup_s=08%2F12%2F2012&lup_d=30

Sent from my iPhone